Talking, smiling, eating together – these are all social activities that are inherent to the human experience. But for some head and neck cancer survivors, they are dreaded tasks. These survivors can ...
According to preliminary data from a multi-institution Phase III trial intensity modulated proton therapy (IMPT) achieved similar clinical outcomes and offered significant patient benefits when ...
New research found patients with certain head and neck cancers lived longer and experienced fewer side effects when treated ...
A new phase III clinical trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people ...
Therapeutic management of locally advanced, recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) is often limited by a rather unfavorable efficacy and toxicity ratio. Since the 1990s ...
A global phase 3 trial is evaluating ASP-1929 photoimmunotherapy with Keytruda for recurrent HNSCC, involving around 400 patients. ASP-1929, an antibody-dye conjugate targeting EGFR, is activated by ...
An interim analysis showed among the 43 evaluable patients, the overall response rate was 37.2%. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to petosemtamab for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback